Thirty years have passed since clinicians started using prostate-specific antigen level as a screening tool for prostate cancer. Over the years, the diagnosis of metastatic disease has decreased dramatically, and there has been a considerable decline in mortality.1,2 However, clinicians have struggled to find the balance between early diagnoses of lethal prostate cancer and overdiagnoses of clinically insignificant disease. Some lessons have been learned from large clinical trials, leading to the adjustment of the age and rate of screening and the development of better tests. In addition, better understanding of risk stratification and the role of active surveillance have improved treatment algorithms. In the recent past, technological advances have facilitated diagnosis. Specifically, multiparametric magnetic resonance imaging (MRI) of the prostate has significantly improved the detection of clinically significant cancer.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Shabsigh A, Lee CT. Closing the Loop on the Role of Multiparametric Magnetic Resonance Imaging–Targeted Prostate Biopsy. JAMA Surg. 2019;154(9):818. doi:10.1001/jamasurg.2019.1735
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: